These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 26276761

  • 1. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
    Harada H, Miyamoto K, Yamashita Y, Taniyama K, Mihara K, Nishimura M, Okada M.
    Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
    [Abstract] [Full Text] [Related]

  • 2. Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non-small cell lung cancer.
    Harada H, Miyamoto K, Yamashita Y, Nakano K, Taniyama K, Miyata Y, Ohdan H, Okada M.
    Cancer; 2013 Feb 15; 119(4):792-8. PubMed ID: 23335114
    [Abstract] [Full Text] [Related]

  • 3. Methylated DLX4 Predicts Response to Pathologic Stage I Non-Small Cell Lung Cancer Resection.
    Harada H, Miyamoto K, Yamashita Y, Taniyama K, Ohdan H, Okada M.
    Ann Thorac Surg; 2015 May 15; 99(5):1746-54. PubMed ID: 25825198
    [Abstract] [Full Text] [Related]

  • 4. DNA methylation markers and early recurrence in stage I lung cancer.
    Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG.
    N Engl J Med; 2008 Mar 13; 358(11):1118-28. PubMed ID: 18337602
    [Abstract] [Full Text] [Related]

  • 5. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
    Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH.
    Cancer Res; 2006 Apr 15; 66(8):4049-54. PubMed ID: 16618724
    [Abstract] [Full Text] [Related]

  • 6. Clinical significance of the methylated cytosine-phosphate-guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer.
    Deng J, Liang H, Ying G, Dong Q, Zhang L, Yu J, Fan D, Hao X.
    J Am Coll Surg; 2014 Nov 15; 219(5):904-13. PubMed ID: 25260683
    [Abstract] [Full Text] [Related]

  • 7. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
    Zhang X, Yang X, Wang J, Liang T, Gu Y, Yang D.
    Int J Clin Exp Pathol; 2015 Nov 15; 8(9):11452-7. PubMed ID: 26617874
    [Abstract] [Full Text] [Related]

  • 8. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
    Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, Lee HY.
    Clin Cancer Res; 2002 Dec 15; 8(12):3669-75. PubMed ID: 12473575
    [Abstract] [Full Text] [Related]

  • 9. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, Motoyama T.
    Lung Cancer; 2007 Oct 15; 58(1):131-8. PubMed ID: 17606310
    [Abstract] [Full Text] [Related]

  • 10. Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.
    Tang X, Yin X, Xiang T, Li H, Li F, Chen L, Ren G.
    Cancer Biomark; 2007 Oct 15; 12(1):11-9. PubMed ID: 23321465
    [Abstract] [Full Text] [Related]

  • 11. Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer.
    Lin YL, Li ZG, He ZK, Guan TY, Ma JG.
    J Int Med Res; 2012 Oct 15; 40(6):2117-23. PubMed ID: 23321168
    [Abstract] [Full Text] [Related]

  • 12. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
    Lin YL, Wang YL, Ma JG, Li WP.
    J Exp Clin Cancer Res; 2014 Aug 22; 33(1):68. PubMed ID: 25927589
    [Abstract] [Full Text] [Related]

  • 13. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B, Sequist L, Lee M, Muzikansky A, Heist R, Iafrate J, Dias-Santagata D, Mathisen D, Lanuti M.
    Ann Thorac Surg; 2013 Sep 22; 96(3):962-8. PubMed ID: 23932319
    [Abstract] [Full Text] [Related]

  • 14. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer.
    Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP, Tong JH, Ying JM, Jin H, To KF, Chan FK, Sung JJ.
    Gastroenterology; 2009 Feb 22; 136(2):640-51.e1. PubMed ID: 19084528
    [Abstract] [Full Text] [Related]

  • 15. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
    Choi N, Son DS, Song I, Lee HS, Lim YS, Song MS, Lim DS, Lee J, Kim H, Kim J.
    Int J Cancer; 2005 Jul 01; 115(4):575-81. PubMed ID: 15700308
    [Abstract] [Full Text] [Related]

  • 16. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S, Sugio K, Uramoto H, Oyama T, Hanagiri T, Morita M, Yasumoto K.
    Cancer; 2006 May 15; 106(10):2190-9. PubMed ID: 16598757
    [Abstract] [Full Text] [Related]

  • 17. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
    Ko E, Lee BB, Kim Y, Lee EJ, Cho EY, Han J, Shim YM, Park J, Kim DH.
    Clin Cancer Res; 2013 Mar 01; 19(5):1204-12. PubMed ID: 23319821
    [Abstract] [Full Text] [Related]

  • 18. Factors associated with recurrence in patients with curatively resected stage I-II lung cancer.
    Koo HK, Jin SM, Lee CH, Lim HJ, Yim JJ, Kim YT, Yang SC, Yoo CG, Han SK, Kim JH, Shim YS, Kim YW.
    Lung Cancer; 2011 Aug 01; 73(2):222-9. PubMed ID: 21168237
    [Abstract] [Full Text] [Related]

  • 19. DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in Non-small cell lung cancer.
    Wu F, Lu M, Qu L, Li DQ, Hu CH.
    Int J Clin Exp Pathol; 2015 Aug 01; 8(5):5457-63. PubMed ID: 26191250
    [Abstract] [Full Text] [Related]

  • 20. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
    Kong F, Gao F, Chen J, Sun Y, Zhang Y, Liu H, Li X, Yang P, Zheng R, Liu G, Jia Y.
    Oncotarget; 2016 Aug 30; 7(35):56193-56199. PubMed ID: 27486880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.